| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Cloud P Paweletz | |
| Bryan C Ulrich | |||
| P2860 | cites work | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 |
| Follow-up of patients with curatively resected colorectal cancer: a practice guideline | Q24641986 | ||
| Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations | Q24678861 | ||
| Digital PCR | Q24685020 | ||
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Q27852116 | ||
| AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Q27853158 | ||
| Rociletinib in EGFR-mutated non-small-cell lung cancer | Q27853159 | ||
| Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement | Q28265041 | ||
| Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 | ||
| Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal Plasma | Q28314918 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 | ||
| Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments | Q30667824 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Detection of cancer DNA in plasma of patients with early-stage breast cancer. | Q33624889 | ||
| About the possible origin and mechanism of circulating DNA apoptosis and active DNA release | Q34100424 | ||
| Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. | Q34168875 | ||
| Minimal residual disease in acute myeloid leukaemia | Q34179265 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement | Q34282601 | ||
| Detection of ultra-rare mutations by next-generation sequencing | Q34291814 | ||
| Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement | Q34394907 | ||
| Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients | Q34483980 | ||
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Q34533164 | ||
| Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement | Q34847160 | ||
| Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment | Q35218647 | ||
| Treatment of recurrent disease in lung cancer | Q35543234 | ||
| Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study | Q35700203 | ||
| Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | Q36000803 | ||
| ??? | Q94720111 | ||
| Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients | Q36508759 | ||
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma | Q36561655 | ||
| Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses | Q36643142 | ||
| Identification of tissue-specific cell death using methylation patterns of circulating DNA | Q36770646 | ||
| ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients | Q37194027 | ||
| Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. | Q37206520 | ||
| Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer | Q37638241 | ||
| Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. | Q37646889 | ||
| Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection | Q37715050 | ||
| CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. | Q37719554 | ||
| Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis | Q38269844 | ||
| Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma | Q38395321 | ||
| Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. | Q40255202 | ||
| Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer | Q40364937 | ||
| A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial | Q40381235 | ||
| Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. | Q40402748 | ||
| Use of research biopsies in clinical trials: are risks and benefits adequately discussed? | Q41264496 | ||
| Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Q41354811 | ||
| Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer | Q41646881 | ||
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. | Q42183079 | ||
| DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | Q46365334 | ||
| Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer | Q48655131 | ||
| IDH2 Mutation in a Patient with Metastatic Colon Cancer. | Q52868333 | ||
| Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma. | Q53103882 | ||
| Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. | Q54537674 | ||
| TP53andKRAS2Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study | Q57037815 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer | Q58813330 | ||
| 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines | Q73080417 | ||
| The origin and mechanism of circulating DNA | Q73808680 | ||
| Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years | Q79193052 | ||
| Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer | Q84872392 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 1 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| lung neoplasm | Q15124212 | ||
| cell-free nucleic acid | Q66981054 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Annals of laboratory medicine | Q26853883 |
| P1476 | title | Cell-Free DNA in Oncology: Gearing up for Clinic | |
| P478 | volume | 38 |
| Q52646444 | Advances in liquid biopsy approaches for early detection and monitoring of cancer. |
| Q92481902 | Clinical applications of liquid biopsies for early lung cancer detection |
| Q91708347 | DNA Methylation Cancer Biomarkers: Translation to the Clinic |
| Q91791862 | Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts |
| Q92472948 | Utilization of Archived Plasma to Detect Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients |
Search more.